Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2006

View Archived Issues

EvoGenix enters technology collaboration agreement with CSL

Confirmatory U.S. phase III study for Sanvar

Partnership to test encapsulated human islets in phase I/II trial

Treatment begins in phase III study of Dyloject for postoperative pain

Cangene awarded U.S. Government contract for botulinum toxin immune globulin

Preclinical atria-selective protective action of RSD-1235 and phase III clinical data to date

Initial increase in vision from baseline with monthly dosing of Lucentis

NDA route planned for Xyotax for women with lung cancer

Fast track designation for talabostat in stage IIIB/IV NSCLC

Positive animal findings for antiinflammatory compound 1-TDC

Treatment begins in phase I/II study of Elacyt in leukemia

New study of tesmilifene with Taxotere in metastatic breast cancer

American Gastroenterological Association recommends Entocort EC

Ostabolin-C demonstrates effects on bone in rats

Therapeutic potential of AAE-581 seen in postmenopausal women

Targeting FKBP38 for neuroprotection

Recent patents report novel analgesic agents

Novel agents for treating neurological disorders disclosed in recent patent literature

Recent patents claim new therapeutic agents for psychological disorders

MabThera recommended for European approval for rheumatoid arthritis

Priority review for Gestiva NDA

Tibolone NDA deemed not approvable

FDA approves reintroduction of Tysabri

ATryn recommended for approval in Europe

Discovery Labs to withdraw Surfaxin MAA

Orally active Met inhibitor shows potential in renal cell carcinoma

Preliminary findings for ImClone's IMC-1121B in advanced cancer

Eltrombopag safe and effective in increasing platelet counts in humans

E-7389, a novel antitubulin agent with potential in breast and lung cancer

Good safety and evidence of antitumor activity described for TSU-68

CXCL7-derived peptide improves bone density and strength in preclinical studies

The CCR1 antagonist BX-471 evaluated in phase II clinical trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...